IDO1 and neoplasm: Inhibitors of the kynurenine pathway can exert anti-tumor effects when combined with other immunotherapies, such as immune checkpoint inhibitors, chemotherapy, and radiotherapy; however, their application in liver diseases is not yet widespread, possibly due to the complex role of IDO in the liver and the lack of sufficient clinical evidence to support their broad use in liver-related diseases.